Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction

Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction

The purpose of this study was to determine the dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with an insufficient compensation of type 2 diabetes mellitus and hypertension in the correction of blood pressure using angiotensin II receptor antagonists for 1 y...

Full description

Bibliographic Details
Main Author:	Pertseva N.O.
Format:	Article
Language:	English
Published:	SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" 2014-11-01
Series:	Medičnì Perspektivi
Subjects:	diabetes mellitus type 2 insufficient compensation arterial hypertension endothelial dysfunction renal function lipidemic profile angiotensin II receptor antagonists
Online Access:	http://medpers.dsma.dp.ua/issues/2014/N4/89-97.pdf

Similar Items

DAMAGE OF RENAL FUNCTION AND DYNAMICS OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INSUFFICIENT GLYCEMIC COMPENSATION UNDER CONDITION OF CORRECTION OF HYPERTENSION WITH ANGIOTENSIN II RECEPTOR ANTAGONISTS
by: N.O. Pertseva
Published: (2014-12-01)

Relationship of endothelial dysfunction with degree of renal function damage and lipidemic profile in patients with type 2 diabetes mellitus and hypertension
by: Pertseva N.O.
Published: (2014-09-01)

Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
by: N. G. Poteshkina, et al.
Published: (2011-10-01)

Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications
by: Miroslav Radenkovic, et al.
Published: (2016-01-01)

Effect of Angiotensin Receptor Inhibitors on Endothelial Dysfunction
by: Alaleh Gheisari, et al.
Published: (2011-10-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA
by: Tanja Kök, et al.
Published: (2002-03-01)

Toxicological evaluations of Stigma maydis (corn silk) aqueous extract on hematological and lipid parameters in Wistar rats
by: Sabiu Saheed, et al.
Published: (2015-01-01)

AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION
by: L. L. Kirichenko, et al.
Published: (2014-02-01)

Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication
by: Jae Hoon Kim, et al.
Published: (2017-03-01)

Ultrastructural changes of platelet granules in patients with type 2 diabetes mellitus and hypertension in applying of angiotensin II receptor antagonists
by: Pertseva N.O.
Published: (2016-06-01)

Sudden Intraoperative Hyperkalemia during Laparoscopic Radical Nephrectomy in a Patient with Underlying Renal Insufficiency
by: Sung Hoon Jung, et al.
Published: (2018-11-01)

Lipidemic Profile Changes over a Two-Year Intervention Period: Who Benefited Most from the Feel4Diabetes Program?
by: Kalliopi Karatzi, et al.
Published: (2020-12-01)

Relationship between the bioavailability and molecular properties of angiotensin II receptor antagonists
by: Trbojević Jovana B., et al.
Published: (2016-01-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

The influence of certain molecular descriptors of fecal elimination of angiotensin II receptor antagonists
by: Trbojević-Stanković Jasna B., et al.
Published: (2015-01-01)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Role of lipid metabolic disturbances for the mechanisms of immune dysregulation and endothelial dysfunction in early forms of chronic cerebrovascular insufficiency
by: E. V. Davydova, et al.
Published: (2020-01-01)

The Angiotensin-Converting Enzyme Gene Polymorphism is Associated with Pregnancy Miscarriage and Placental Insufficiency
by: Bespalova O, et al.
Published: (2007-04-01)

IN SILICO EVALUATION OF ANGIOTENSIN II RECEPTOR ANTAGONIST’S PLASMA PROTEIN BINDING USING COMPUTED MOLECULAR DESCRIPTORS
by: Jadranka Odović, et al.
Published: (2014-03-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

Renal actions of angiotensin-(1-7)
by: A.C. Simões-e-Silva, et al.
Published: (1997-04-01)

Renin-angiotensin system antagonists, glomerular filtration rate and blood pressure
by: D.D. Ivanov
Published: (2018-02-01)

Angiotensin II Induces Oxidative Stress and Endothelial Dysfunction in Mouse Ophthalmic Arteries via Involvement of AT1 Receptors and NOX2
by: Michael Birk, et al.
Published: (2021-08-01)

Dynamics of Endothelial Function Impairment in Patients with Initial Poor Compensation of Type 2 Diabetes Mellitus in Correction of Hypertension with Angiotensin II Receptor Antagonists during a year
by: N.O. Pertseva
Published: (2014-10-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

Systemic Administration of Insulin Receptor Antagonist Results in Endothelial and Perivascular Adipose Tissue Dysfunction in Mice
by: Bartosz Proniewski, et al.
Published: (2021-06-01)

Protective Effects of Short-Chain Fatty Acids on Endothelial Dysfunction Induced by Angiotensin II
by: Iñaki Robles-Vera, et al.
Published: (2020-04-01)

The role of tissue renin angiotensin aldosterone system in the development of endothelial dysfunction and arterial stiffness
by: Annayya R Aroor, et al.
Published: (2013-10-01)

Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
by: Byung Chul Yu, et al.
Published: (2018-09-01)

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19
by: Azadeh Khalili, et al.
Published: (2021-07-01)

Traditional Chinese medicine based on Zheng differentiation versus angiotensin receptor blocker/angiotensin-converting enzyme antagonist in efficacy of treating diabetic kidney disease: A meta-analysis of randomized clinical trials
by: Wei-Jun Huang, et al.
Published: (2019-01-01)

Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice
by: Agnieszka Kij, et al.
Published: (2021-08-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension
by: Qian Xu, et al.
Published: (2021-09-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

Loxoprofen Sodium Alleviates Oxidative Stress and Apoptosis Induced by Angiotensin II in Human Umbilical Vein Endothelial Cells (HUVECs)
by: Ji C, et al.
Published: (2020-11-01)

Intraoperative angioedema induced by angiotensin II receptor blocker: a case report
by: Ala”a Alhowary, et al.
Published: (2018-09-01)

Clinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combination
by: M. V. Leonova
Published: (1970-01-01)